8-6-13 8:00 AM EDT | Email Article

RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, reported operating results for the second quarter of 2013 as follows:

Quarterly Highlights:

  • Achieved quarterly revenues of $42.3 million.
  • Achieved quarterly revenues of $11.2 million in the spine business, a 15 percent increase over the second quarter of 2012.
  • Announced acquisition of Pioneer Surgical Technology Inc. (Pioneer), a leading medical technology company.
  • Launched Fortiva™ porcine dermis implant for hernia repair; announced first human implantation.
  • Achieved sterilization milestone – more than 5 million biologic implants sterilized with zero incidence of implant associated infection.
  • Settled substantially all of the remaining Biomedical Tissue Services Ltd. (BTS) lawsuits, which brings to conclusion any material risk related to these proceedings.

Worldwide revenues of $42.3 million for the second quarter of 2013 decreased 6 percent compared to the second quarter of 2012. Domestic revenues of $37.4 million for the second quarter of 2013 decreased 5 percent compared to the second quarter of 2012, primarily due to weakness in the sports medicine, surgical specialties and bone grafts substitutes and general orthopedic businesses, offset by strength in the spine business. International revenues of $4.9 million for the second quarter of 2013 decreased 18 percent as compared to the second quarter of 2012. On a constant currency basis, international revenues for the second quarter of 2013 decreased 20 percent as compared to the second quarter of 2012.

For the second quarter of 2013, the company reported net loss of $3.0 million and net loss per fully diluted share of $0.05, based on 56.3 million fully diluted shares outstanding, compared to net income of $1.3 million or $0.02 per fully diluted share for the second quarter of 2012, based on 56 million fully diluted shares outstanding.

In 2005, the company was named as a party, along with a number of other recovery and processor defendants in lawsuits relating to the tissue recovery practices of BTS, an unaffiliated recovery agency. During the second quarter of 2012, the company accrued a pre-tax litigation settlement charge of $2.35 million, or $0.03 per fully diluted share to settle certain cases related to these proceedings. During the second quarter of 2013, the company accrued a pre-tax litigation settlement charge of $3 million, or $0.03 cents per fully diluted share to settle substantially all of the remaining lawsuits relating to these proceedings. This brings to conclusion any material risk related to BTS.

Also during the second quarter of 2013, the company accrued a pre-tax expense of $1.5 million for certain fees related to the acquisition of Pioneer.

Excluding the litigation settlement charge of $3 million and the expense related to the acquisition of Pioneer of $1.5 million, the company reported net income of $0.00 per fully diluted share.

“While second quarter revenues were in line with our expectations, net income fell short,” said Brian K. Hutchison, president and chief executive officer of RTI. “The shortfall in net income for the period was due to the $3 million BTS litigation settlement charge, the $1.5 million expense related to the acquisition of Pioneer, as well as lower gross margins primarily related to the mix of implants distributed and the continued investment in the business to launch our new surgical specialties distribution force.”

Fiscal 2013 and Third Quarter Outlook

Based on the acquisition of Pioneer and results from the first six months the company is revising its full year revenue guidance for 2013. The company now expects full year revenue guidance for 2013 to be between $211 million to $215 million, as compared to prior guidance of $179 million to $182 million. Full year net loss after preferred dividends per fully diluted share applicable to common shareholders is expected to be in the range of $0.13 to $0.11, based on 56.7 million fully diluted shares outstanding, as compared to prior guidance of full year net income per fully diluted share applicable to common shareholders of $0.17 to $0.19. Excluding certain acquisition related expenses, certain purchase accounting adjustments, and the BTS litigation settlement charge taken in the second quarter, full year net income after preferred dividends per fully diluted share applicable to common shareholders is expected to be in the range of $0.05 to $0.07. Throughout the remainder 2013, the company will continue to integrate the Pioneer business, make investments in distribution, marketing and development activities to support the launch of new products and to expand its presence in general orthopedics.

For the third quarter of 2013, the company expects revenues to be between $59 million and $61 million and net loss after preferred dividends per fully diluted share applicable to common shareholders to be approximately $0.10, based on 56.8 million fully diluted shares outstanding. Excluding certain acquisition related expenses and certain purchase accounting adjustments, third quarter net income after preferred dividends is expected to be approximately $0.00 per fully diluted share applicable to common shareholders.

Conference Call

RTI will host a conference call and simultaneous audio webcast to discuss the second quarter results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on the RTI website following the call.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to advancing science, safety and innovation, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in more than 47 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of Advamed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.

       
RTI SURGICAL, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
 
Three Months EndedSix Months Ended
June 30,June 30,
2013201220132012
Revenues:
Tissue distribution $ 40,809 $ 43,711 $ 77,897 $ 85,832
Other revenues   1,500     1,486     4,834     3,108  
Total revenues 42,309 45,197 82,731 88,940
Costs of processing and distribution   23,073     23,526     44,299     47,163  
Gross profit   19,236     21,671     38,432     41,777  
Expenses:
Marketing, general and administrative 15,695 14,294 30,718 28,668
Research and development 3,341 3,343 6,452 6,170
Asset abandonments - 2 - 18
Litigation settlement 3,000 2,350 3,000 2,350
Acquisition expenses   1,495     -     1,495     -  
Total operating expenses   23,531     19,989     41,665     37,206  
Operating (loss) income   (4,295)   1,682     (3,233)   4,571  
Total other income - net   3     51     3     106  
(Loss) income before income tax benefit (provision) (4,292 ) 1,733 (3,230 ) 4,677
Income tax benefit (provision)   1,293     (412)   1,693     (1,354)
Net (loss) income $(2,999)$1,321   $(1,537)$3,323  
 
Net (loss) income per common share - basic $(0.05)$0.02   $(0.03)$0.06  
Net (loss) income per common share - diluted $(0.05)$0.02   $(0.03)$0.06  
Weighted average shares outstanding - basic   56,272,327     55,857,858     56,146,608     55,785,171  
Weighted average shares outstanding - diluted   56,272,327     56,027,272     56,146,608     55,973,094  
 
       
RTI SURGICAL, INC. AND SUBSIDIARIES
Reconciliation of Net (Loss) Income and Net (Loss) Income Per Diluted Share to
Adjusted Net (Loss) Income and Adjusted Net (Loss) Income Per Diluted Share
(In thousands except per share data)
(Unaudited)
 
 
Three Months Ended
June 30, 2013June 30, 2012
AmountAmount
Netper DilutedNetper Diluted
(Loss) IncomeShare(Loss) IncomeShare
 
As reported $ (2,999 ) $ (0.05 ) $ 1,321 $ 0.02
Litigation settlement charge,
net of tax effect (1) 1,822 0.03 1,444 0.03
Acquisition expenses
net of tax effect (2)   908     0.02     -     -
Adjusted $(269)$(0.00)$2,765   $0.05
 
 
 
Six Months Ended
June 30, 2013June 30, 2012
AmountAmount
Netper DilutedNetper Diluted
(Loss) IncomeShare(Loss) IncomeShare
 
As reported $ (1,537 ) $ (0.03 ) $ 3,323 $ 0.06
Litigation settlement charge,
net of tax effect (1) 1,822 0.03 1,444 0.03
Acquisition expenses
net of tax effect (2)   908     0.02     -     -
Adjusted $1,193   $0.02   $4,767   $0.09
 
 
 
 
 
(1) Litigation settlement charge, net of tax effect, as follows:
 
Litigation settlement charge $ 3,000 $ 2,350
Tax effect on litigation settlement charge   (1,178)   (906)
Litigation settlement charge, net of tax effect $1,822   $1,444  
 
 
(2) Acquisition expenses, net of tax effect, as follows:
 
Acquisition expenses $ 1,495
Tax effect on acquisition expenses   (587)
Acquisition expenses, net of tax effect $908  
 

Use of Non-GAAP Financial Measures

To supplement RTI Surgical’s condensed consolidated financial statements presented on a GAAP basis, the company discloses certain non-GAAP financial measures that exclude certain amounts, including non-GAAP net (loss) income and non-GAAP net (loss) income per fully diluted share. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP measures are included in the reconciliation above.

The following are explanations of the adjustments that management excluded as part of the non-GAAP measures for the three and six month period ended June 30, 2013 as well as the reasons for excluding the individual item:

2013 Litigation settlement – This adjustment represents a charge and relates to a litigation settlement of certain BTS related lawsuits. Management removes the amount of the litigation settlement charge from the Company’s operating results to assist in assessing its operating performance in the year-to-date period and to supplement a comparison to the Company’s past operating performance.

2013 Acquisition expenses – This adjustment represents a charge and relates to certain fees associated with the acquisition of Pioneer. Management removes the amount of these one-time fees from the Company’s operating results to assist in assessing its operating performance in the year-to-date period and to supplement a comparison to the Company’s past operating performance.

2012 Litigation settlement – This adjustment represents a charge and relates to a litigation settlement of certain BTS related lawsuits. Management removes the amount of the litigation settlement charge from the Company’s operating results to assist in assessing its operating performance in the prior year periods to supplement a comparison to the Company’s current operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income and non-GAAP net income per fully diluted share should not be considered in isolation, or as a replacement for GAAP measures.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income and non-GAAP net income per fully diluted share in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making which excludes the litigation settlement charge. The Company further believes that providing this information better enables RTI Surgical’s investors to understand the Company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.

       
RTI SURGICAL, INC. AND SUBSIDIARIES
Condensed Consolidated Revenues
(In thousands)
(Unaudited)
 
Three Months EndedSix Months Ended
June 30,June 30,
2013201220132012
 
Revenues from tissue distribution:
Sports medicine $ 11,657 $ 13,337 $ 22,168 $ 26,762
Spine 11,221 9,785 21,320 18,345
Surgical specialties 6,875 8,459 13,829 16,256
Bone graft substitutes and general orthopedic 6,050 7,016 11,401 14,031
Dental 5,006 5,114 9,179 10,438
Other revenues   1,500   1,486   4,834   3,108
Total revenues $ 42,309 $ 45,197 $ 82,731 $ 88,940
Domestic revenues 37,413 39,191 73,527 77,064
International revenues   4,896   6,006   9,204   11,876
Total revenues $ 42,309 $ 45,197 $ 82,731 $ 88,940
 
   
RTI SURGICAL, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
June 30,December 31,
20132012
Assets
Cash and cash equivalents $ 39,393 $ 49,696
Accounts receivable - net 21,938 21,694
Inventories - net 79,357 76,509
Prepaid and other current assets   20,064     18,673  
Total current assets 160,752 166,572
 
Property, plant and equipment - net 51,350 49,644
Other assets - net   24,926     25,193  
Total assets $237,028   $241,409  
 
Liabilities and Stockholders' Equity
Accounts payable $ 13,532 $ 11,949
Accrued expenses and other current liabilities 20,908 25,397
Current portion of long-term obligations   27     116  
Total current liabilities 34,467 37,462
 
Deferred revenue 17,854 18,780
Long-term liabilities   1,330     1,175  
Total liabilities 53,651 57,417
Stockholders' equity:
Common stock and additional paid-in capital 415,741 414,504
Accumulated other comprehensive loss (2,091 ) (1,776 )
Accumulated deficit   (230,273)   (228,736)
Total stockholders' equity   183,377     183,992  
Total liabilities and stockholders' equity $237,028   $241,409  
 
       
RTI SURGICAL, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 
Three Months EndedSix Months Ended
June 30,June 30,
2013201220132012
Cash flows from operating activities:
Net (loss) income $ (2,999 ) $ 1,321 $ (1,537 ) $ 3,323
Adjustments to reconcile net (loss) income to net cash
provided by (used in) operating activities:
Depreciation and amortization expense 2,095 1,970 4,123 3,879
Stock-based compensation 584 525 1,069 1,050
Amortization of deferred revenue (1,132 ) (1,164 ) (4,047 ) (2,328 )
Other items to reconcile to net cash
provided by (used in) operating activities   4,731     2,163     (4,392)   3,256  
Net cash provided by (used in) operating activities   3,279     4,815     (4,784)   9,180  
Cash flows from investing activities:
Purchases of property, plant and equipment (2,164 ) (1,806 ) (4,872 ) (4,609 )
Acquired intangible asset costs   (136)   (311)   (234)   (376)
Net cash used in investing activities   (2,300)   (2,117)   (5,106)   (4,985)
Cash flows from financing activities:
Proceeds from exercise of common stock options 128 114 213 214
Payments on long-term obligations (11 ) (95 ) (93 ) (294 )
Other financing activities   (496)   -     (519)   (20)
Net cash (used in) provided by financing activities   (379)   19     (399)   (100)
Effect of exchange rate changes on cash and cash equivalents   (9)   (74)   (14)   (42)
Net increase (decrease) in cash and cash equivalents 591 2,643 (10,303 ) 4,053
Cash and cash equivalents, beginning of period   38,802     47,588     49,696     46,178  
Cash and cash equivalents, end of period $39,393   $50,231   $39,393   $50,231  
 

RTI Surgical Inc.
Robert Jordheim, Chief Financial Officer
rjordheim@rtix.com
or
Wendy Crites Wacker, APR
Executive Director, Global Corporate and Marketing Communications
wwacker@rtix.com
386-418-8888

Copyright Business Wire 2013
Add a Comment

News   More...

Securities related to this article
RTI Surgical Inc View rtix Stock Quote
RTI Surgical Inc View rtix Stock Quote
 
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - - RTI Surgical Announces 2013 Second Quarter Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: RTI International Metals, Inc. Announces Delay in Filing Second Quarter 2013 Form 10-Q  |  Next: RTI Surgical Announces Successful Resolution to FDA Warning Letter for Alachua, Fla. Facility